Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jul-Aug;21(4):262-3.
doi: 10.4103/1319-3767.161637.

Hepatitis C position statement: Taking a stand and standing by it

Faisal M Sanai  1 , Abdullah S Alghamdi, Mohammed Y Alghamdi
Affiliations
Comment

Hepatitis C position statement: Taking a stand and standing by it

Faisal M Sanai et al. Saudi J Gastroenterol. 2015 Jul-Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Al-Judaibi B. Ribavirin-free treatment may soon be a reality. Saudi J Gastroenterol. 2015;21:260–1. - PMC - PubMed
    1. Alghamdi AS, Alqutub A, Abaalkhail F, Sanai FM, Alghamdi H, Altraif I, et al. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection. Saudi J Gastroenterol. 2015;21:60–3. - PMC - PubMed
    1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95. - PubMed
    1. AASLD/IDSA/IAS. USA. Recommendations for testing, managing, and treating hepatitis C. [Last accessed on 2015 Feb 13]. Available from: http://www.hcvguidelines.org .
    1. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial. Lancet. 2015;385:2502–9. - PubMed